Last reviewed 2026-04-22 · How we verify

Femoston® 1, Femoston® 2

Femoston is a hormone replacement therapy combining estradiol and dydrogesterone to replace declining estrogen and progesterone in postmenopausal women.

Femoston is a hormone replacement therapy combining estradiol and dydrogesterone to replace declining estrogen and progesterone in postmenopausal women. Used for Vasomotor symptoms of menopause (hot flushes, night sweats), Postmenopausal osteoporosis prevention, Genitourinary symptoms of menopause.

At a glance

Mechanism of action

Femoston delivers micronized 17β-estradiol (a bioidentical estrogen) combined with dydrogesterone (a synthetic progestin) in a sequential or continuous regimen. The estradiol component alleviates vasomotor symptoms and supports bone health, while dydrogesterone provides endometrial protection in women with an intact uterus, reducing the risk of endometrial hyperplasia and cancer.

Approved indications

• Vasomotor symptoms of menopause (hot flushes, night sweats)
• Postmenopausal osteoporosis prevention
• Genitourinary symptoms of menopause

Common side effects

• Breast tenderness
• Headache
• Nausea
• Vaginal bleeding or spotting
• Abdominal discomfort

Key clinical trials

• Comparative Study to Evaluate the Efficacy and Safety of the Fixed-dose Combination of Estradiol / Dydrogesterone in Perimenopausal Women (PHASE4)
• Oral Verses Patch Trial In Menopausal Women - Individualisation of Oestrogen Therapy (PHASE4)
• The Effects of Tualang Honey on Postmenopausal Women (PHASE2, PHASE3)

Primary sources

Every claim on this page is sourced from regulatory or scientific primary sources. See our editorial policy for full methodology.